These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 7710667

  • 1. The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: a hypothesis.
    Enochs WS, Sarna T, Zecca L, Riley PA, Swartz HM.
    J Neural Transm Park Dis Dement Sect; 1994; 7(2):83-100. PubMed ID: 7710667
    [Abstract] [Full Text] [Related]

  • 2. Total and paramagnetic metals in human substantia nigra and its neuromelanin.
    Zecca L, Swartz HM.
    J Neural Transm Park Dis Dement Sect; 1993; 5(3):203-13. PubMed ID: 8396395
    [Abstract] [Full Text] [Related]

  • 3. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease.
    Faucheux BA, Martin ME, Beaumont C, Hauw JJ, Agid Y, Hirsch EC.
    J Neurochem; 2003 Sep; 86(5):1142-8. PubMed ID: 12911622
    [Abstract] [Full Text] [Related]

  • 4. Purified human neuromelanin, synthetic dopamine melanin as a potential model pigment, and the normal human substantia nigra: characterization by electron paramagnetic resonance spectroscopy.
    Enochs WS, Nilges MJ, Swartz HM.
    J Neurochem; 1993 Jul; 61(1):68-79. PubMed ID: 8390568
    [Abstract] [Full Text] [Related]

  • 5. Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease.
    Zucca FA, Segura-Aguilar J, Ferrari E, Muñoz P, Paris I, Sulzer D, Sarna T, Casella L, Zecca L.
    Prog Neurobiol; 2017 Aug; 155():96-119. PubMed ID: 26455458
    [Abstract] [Full Text] [Related]

  • 6. The enigma of neuromelanin in Parkinson's disease substantia nigra.
    Youdim MB, Ben-Shachar D, Riederer P.
    J Neural Transm Suppl; 1994 Aug; 43():113-22. PubMed ID: 7884393
    [Abstract] [Full Text] [Related]

  • 7. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM, Ophof A, Broe M, Jensen PH, Kettle E, Fedorow H, Cartwright MI, Griffiths FM, Shepherd CE, Double KL.
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [Abstract] [Full Text] [Related]

  • 8. Neuromelanin: Its role in the pathogenesis of idiopathic Parkinson's disease and potential as a therapeutic target.
    Mitra R, Premraj L, Khoo TK.
    Parkinsonism Relat Disord; 2023 Jul; 112():105448. PubMed ID: 37236833
    [Abstract] [Full Text] [Related]

  • 9. The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems.
    Zareba M, Bober A, Korytowski W, Zecca L, Sarna T.
    Biochim Biophys Acta; 1995 Jun 09; 1271(2-3):343-8. PubMed ID: 7605801
    [Abstract] [Full Text] [Related]

  • 10. Toxic Feedback Loop Involving Iron, Reactive Oxygen Species, α-Synuclein and Neuromelanin in Parkinson's Disease and Intervention with Turmeric.
    Jansen van Rensburg Z, Abrahams S, Bardien S, Kenyon C.
    Mol Neurobiol; 2021 Nov 09; 58(11):5920-5936. PubMed ID: 34426907
    [Abstract] [Full Text] [Related]

  • 11. Modifications of the iron-neuromelanin system in Parkinson's disease.
    Fasano M, Bergamasco B, Lopiano L.
    J Neurochem; 2006 Feb 09; 96(4):909-16. PubMed ID: 16417570
    [Abstract] [Full Text] [Related]

  • 12. New face of neuromelanin.
    Double KL, Halliday GM.
    J Neural Transm Suppl; 2006 Feb 09; (70):119-23. PubMed ID: 17017518
    [Abstract] [Full Text] [Related]

  • 13. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK, Knudsen K, Lillethorup TP, Landau AM, Parbo P, Fedorova T, Audrain H, Bender D, Østergaard K, Brooks DJ, Borghammer P.
    Brain; 2016 Jul 09; 139(Pt 7):2039-49. PubMed ID: 27190023
    [Abstract] [Full Text] [Related]

  • 14. Antioxidant action of neuromelanin: the mechanism of inhibitory effect on lipid peroxidation.
    Korytowski W, Sarna T, Zar ba M.
    Arch Biochem Biophys; 1995 May 10; 319(1):142-8. PubMed ID: 7771778
    [Abstract] [Full Text] [Related]

  • 15. Neuromelanin and Parkinson's disease.
    Marsden CD.
    J Neural Transm Suppl; 1983 May 10; 19():121-41. PubMed ID: 6321645
    [Abstract] [Full Text] [Related]

  • 16. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease.
    Zecca L, Casella L, Albertini A, Bellei C, Zucca FA, Engelen M, Zadlo A, Szewczyk G, Zareba M, Sarna T.
    J Neurochem; 2008 Aug 10; 106(4):1866-75. PubMed ID: 18624918
    [Abstract] [Full Text] [Related]

  • 17. Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson's disease.
    Biondetti E, Gaurav R, Yahia-Cherif L, Mangone G, Pyatigorskaya N, Valabrègue R, Ewenczyk C, Hutchison M, François C, Arnulf I, Corvol JC, Vidailhet M, Lehéricy S.
    Brain; 2020 Sep 01; 143(9):2757-2770. PubMed ID: 32856056
    [Abstract] [Full Text] [Related]

  • 18. Neuromelanin in Parkinson's Disease: from Fenton Reaction to Calcium Signaling.
    Knörle R.
    Neurotox Res; 2018 Feb 01; 33(2):515-522. PubMed ID: 28879408
    [Abstract] [Full Text] [Related]

  • 19. [The role of neuromelanin in Parkinson's disease--new concepts].
    Stepień K, Dzierzega-Lecznar A, Tam I.
    Wiad Lek; 2007 Feb 01; 60(11-12):563-9. PubMed ID: 18540183
    [Abstract] [Full Text] [Related]

  • 20. Interaction of neuromelanin and iron in substantia nigra and other areas of human brain.
    Zecca L, Shima T, Stroppolo A, Goj C, Battiston GA, Gerbasi R, Sarna T, Swartz HM.
    Neuroscience; 1996 Jul 01; 73(2):407-15. PubMed ID: 8783258
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.